Role of docosahexaenoic acid treatment in improving liver histology in pediatric nonalcoholic fatty liver disease

PLoS One. 2014 Feb 4;9(2):e88005. doi: 10.1371/journal.pone.0088005. eCollection 2014.

Abstract

Introduction: Nonalcoholic fatty liver disease (NAFLD) is one of the most important causes of liver-related morbidity and mortality in children. Recently, we have reported the effects of docosahexaenoic acid (DHA), the major dietary long-chain polyunsaturated fatty acids, in children with NAFLD. DHA exerts a potent anti-inflammatory activity through the G protein-coupled receptor (GPR)120. Our aim was to investigate in pediatric NAFLD the mechanisms underlying the effects of DHA administration on histo-pathological aspects, GPR120 expression, hepatic progenitor cell activation and macrophage pool.

Patients and methods: 20 children with untreated NAFLD were included. Children were treated with DHA for 18 months. Liver biopsies before and after the treatment were analyzed. Hepatic progenitor cell activation, macrophage pool and GPR120 expression were evaluated and correlated with clinical and histo-pathological parameters.

Results: GPR120 was expressed by hepatocytes, liver macrophages, and hepatic progenitor cells. After DHA treatment, the following modifications were present: i) the improvement of histo-pathological parameters such as NAFLD activity score, ballooning, and steatosis; ii) the reduction of hepatic progenitor cell activation in correlation with histo-pathological parameters; iii) the reduction of the number of inflammatory macrophages; iv) the increase of GPR120 expression in hepatocytes; v) the reduction of serine-311-phosphorylated nuclear factor kappa B (NF-κB) nuclear translocation in hepatocytes and macrophages in correlation with serum inflammatory cytokines.

Conclusions: DHA could modulate hepatic progenitor cell activation, hepatocyte survival and macrophage polarization through the interaction with GPR120 and NF-κB repression. In this scenario, the modulation of GPR120 exploits a novel crucial role in the regulation of the cell-to-cell cross-talk that drives inflammatory response, hepatic progenitor cell activation and hepatocyte survival.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Anti-Inflammatory Agents / pharmacology
  • Child
  • Cytokines / genetics
  • Cytokines / metabolism
  • Docosahexaenoic Acids / pharmacology*
  • Fatty Liver / drug therapy*
  • Fatty Liver / genetics
  • Fatty Liver / metabolism
  • Fatty Liver / pathology*
  • Female
  • Hepatocytes / drug effects
  • Hepatocytes / metabolism
  • Hepatocytes / pathology
  • Humans
  • Inflammation / drug therapy
  • Inflammation / genetics
  • Inflammation / metabolism
  • Inflammation / pathology
  • Liver / drug effects*
  • Liver / metabolism
  • Liver / pathology*
  • Macrophages / drug effects
  • Macrophages / metabolism
  • Macrophages / pathology
  • Male
  • NF-kappa B / genetics
  • NF-kappa B / metabolism
  • Non-alcoholic Fatty Liver Disease
  • Receptors, G-Protein-Coupled / genetics
  • Receptors, G-Protein-Coupled / metabolism
  • Stem Cells / drug effects
  • Stem Cells / microbiology
  • Stem Cells / pathology

Substances

  • Anti-Inflammatory Agents
  • Cytokines
  • FFAR4 protein, human
  • NF-kappa B
  • Receptors, G-Protein-Coupled
  • Docosahexaenoic Acids

Grants and funding

Grant support: E. Gaudio was supported by research project grant from the University “Sapienza” of Rome, FIRB grant # RBAP10Z7FS_001 and by PRIN grant # 2009X84L84_001. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.